Valve is changing the frequency and content of Deadlock updates going forward, and this is good for the long term health of ...

Valve's SteamOS officially expands to third-party devices, with an upcoming handheld gaming PC set to ship with the Steam ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

( MENAFN - IANS) New Delhi, Jan 8 (IANS) Kala-azar or visceral leishmaniasis -- a deadly neglected tropical disease -- can be ...

Combining Adderall with other CNS stimulants, such as caffeine, can increase the risk of side effects, including elevated ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports.

Shares of Vir Biotechnology, Inc. (NASDAQ: VIR) surged 29% following the release of encouraging safety and efficacy data from ongoing dose escalation trials for i ...